Cepheid (CPHD) Stock Rating Upgraded by TheStreet
Cepheid (NASDAQ:CPHD) was upgraded by TheStreet from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
A number of other equities research analysts also recently issued reports on the stock. Robert W. Baird downgraded shares of Cepheid from an “outperform” rating to a “neutral” rating and set a $53.00 target price for the company. in a report on Monday, September 12th. Jefferies Group boosted their target price on shares of Cepheid from $28.00 to $34.00 and gave the company a “hold” rating in a report on Wednesday, August 17th. Needham & Company LLC cut shares of Cepheid from a “buy” rating to a “hold” rating in a research report on Tuesday, September 6th. Craig Hallum cut shares of Cepheid from a “buy” rating to a “hold” rating in a research report on Tuesday, September 6th. Finally, Piper Jaffray Cos. cut shares of Cepheid from an “overweight” rating to a “neutral” rating in a research report on Tuesday, September 6th. Seventeen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $41.83.
Cepheid (NASDAQ:CPHD) opened at 52.73 on Wednesday. The stock has a 50 day moving average of $44.15 and a 200 day moving average of $34.60. Cepheid has a one year low of $25.09 and a one year high of $53.91. The firm’s market capitalization is $3.85 billion.
Cepheid (NASDAQ:CPHD) last released its earnings results on Thursday, July 28th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.19. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The firm earned $146 million during the quarter, compared to the consensus estimate of $145.82 million. During the same period in the previous year, the firm earned ($0.06) earnings per share. Cepheid’s revenue was up 10.2% compared to the same quarter last year. Analysts forecast that Cepheid will post $0.33 earnings per share for the current year.
In other news, VP Scott A. Campbell sold 746 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $36.71, for a total transaction of $27,385.66. Following the completion of the transaction, the vice president now owns 10,721 shares in the company, valued at $393,567.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.16% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Cepheid during the fourth quarter valued at approximately $32,233,000. Boston Advisors LLC purchased a new position in Cepheid during the first quarter valued at approximately $423,000. Granite Investment Partners LLC purchased a new position in Cepheid during the first quarter valued at approximately $863,000. Pacad Investment Ltd. purchased a new position in Cepheid during the first quarter valued at approximately $544,000. Finally, TIAA CREF Investment Management LLC raised its position in Cepheid by 7.3% in the first quarter. TIAA CREF Investment Management LLC now owns 337,668 shares of the company’s stock valued at $11,265,000 after buying an additional 23,056 shares in the last quarter. Institutional investors and hedge funds own 95.32% of the company’s stock.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Stock Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related stocks with our FREE daily email newsletter.